Table 4.
Crude and adjusted OR and 95% CI of the association between FSC use and incident glaucoma between 2003 and 2006
| FSC | Crude OR | 95% CI | Adjusted OR | 95% CI |
|---|---|---|---|---|
| Ever use in the last year | ||||
| No use | Reference | – | Reference | – |
| Use | 0.84 | (0.62–1.15) | 0.68 | (0.45–1.01) |
| Last use prior to index date (days) | ||||
| No use | Reference | – | Reference | – |
| 12 days | 1.02 | (0.61–1.71) | 1.00 | (0.53–1.89) |
| 13–25 days | 0.92 | (0.52–1.62) | 0.67 | (0.34–1.30) |
| 26–52 days | 0.54 | (0.3–0.97) | 0.55 | (0.28–1.09) |
| 53–365 days | 0.98 | (0.58–1.65) | 0.81 | (0.44–1.52) |
| Duration of use (days) | ||||
| No use | Reference | – | Reference | – |
| 1–90 | 1.14 | (0.66–1.97) | 1.02 | (0.54–1.90) |
| 91–180 | 0.62 | (0.36–1.08) | 0.50 | (0.26–0.96) |
| 181–270 | 0.68 | (0.36–1.28) | 0.52 | (0.25–1.08) |
| ≥271 | 0.99 | (0.61–1.59) | 0.75 | (0.42–1.34) |
| Number of prescriptions | ||||
| No prescriptions in last year | Reference | – | Reference | – |
| 1–3 | 1.14 | (0.66–1.97) | 1.01 | (0.54–1.89) |
| 4–6 | 0.63 | (0.36–1.10) | 0.49 | (0.26–0.93) |
| 7–9 | 0.70 | (0.38–1.30) | 0.50 | (0.24–1.03) |
| ≥10 | 0.96 | (0.59–1.56) | 0.72 | (0.39–1.30) |
Notes: Population includes patients with COPD in the GPRD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and number of years in the cohort prior to the event of interest. Model adjusted for other inhaled corticosteroids, asthma, long-acting beta agonists, short-acting bronchodilators, oral corticosteroids, BMI, smoking status, statin use, depression, diabetes, oxygen, nebulizer, and count of antibiotic prescriptions.
Abbreviations: BMI, body mass index; CI, confidence interval; FSC, fluticasone propionate/salmeterol fixed-dose combination; GPRD, General Practice Research Database OR, odds ratio.